Trial Profile
A retrospective study of Buprenorphine/naloxone in opioid dependent patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2016
Price :
$35
*
At a glance
- Drugs Buprenorphine/naloxone (Primary)
- Indications Opioid-related disorders
- Focus Therapeutic Use
- Acronyms REZOLV
- 21 Sep 2016 New trial record
- 02 Sep 2016 Results published in the Media Release